Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Aegerion Pharmaceuticals

Related AEGR
Mid-Afternoon Market Update: Dow Falls Over 200 Points; Catabasis Shares Spike Higher
15 Biggest Mid-Day Gainers For Thursday

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR), and raised its price target from $22.00 to $24.00.

Jefferies noted, “At its investor event in New York on 10/23/12, AEGR focused on clinical aspects of lomitapide in HoFH, hosting a panel of 2 lipidologists. There was no commercial agenda. AEGR expects to provide its commercial strategy in early-January 2013 as it is confident of FDA approval of lomitapide by PDUFA date 12/29/12 and EU approval in 1H13. Lomitapide received positive FDA panel votes (13-2 in favor) on 10/17/12.”

Aegerion Pharmaceuticals closed on Tuesday at $20.45.

Latest Ratings for AEGR

Feb 2016Bank of AmericaDowngradesNeutralUnderperform
Dec 2015GuggenheimUpgradesSellBuy
Nov 2015Bank of AmericaUpgradesUnderperformNeutral

View More Analyst Ratings for AEGR
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (AEGR)

View Comments and Join the Discussion!